
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is currently undergoing a reverse split and working to regain compliance with NYSE American requirements, while also seeking to translate platform validation into commercial success. The company's current cash position may fund operations through mid-2026, but further capital will be needed for sustained growth. While a recent peer-reviewed publication and potential opportunities in trauma and critical care may be positive indicators, the company's success will ultimately depend on its ability to drive clinical adoption and generate revenue.
Bears say
VolitionRX is being downgraded to Hold due to its recent announcement of a 1-for-20 reverse stock split, which is typically seen as a negative development and can result in decreased market value and liquidity. Additionally, the company has faced financial and listing concerns and has not met revenue expectations. While they have potential licensing deals in the works, it may not be enough to offset these challenges in the short term.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares